Aurinia Pharmaceuticals Inc.

NasdaqGM AUPH

Aurinia Pharmaceuticals Inc. Revenue for the year ending December 31, 2023: USD 175.51 M

Aurinia Pharmaceuticals Inc. Revenue is USD 175.51 M for the year ending December 31, 2023, a 30.95% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Aurinia Pharmaceuticals Inc. Revenue for the year ending December 31, 2022 was USD 134.03 M, a 193.89% change year over year.
Aurinia Pharmaceuticals Inc. Revenue for the year ending December 31, 2021 was USD 45.60 M, a -9.00% change year over year.
Aurinia Pharmaceuticals Inc. Revenue for the year ending December 31, 2020 was USD 50.12 M, a 15,660.38% change year over year.
Aurinia Pharmaceuticals Inc. Revenue for the year ending December 31, 2019 was USD 318.00 K, a -31.32% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqGM: AUPH

Aurinia Pharmaceuticals Inc.

CEO	Mr. Peter S. Greenleaf M.B.A.
IPO Date	Sept. 3, 2014
Location	Canada
Headquarters	4464 Markham Street
Employees	300
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Key trends

Past 5 years